Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
At a still earlier stage of development, we found some exciting anti-pseudomonal compounds. First, there is BAL-30072, a sulfactam-derivative. It has an interesting dual MoA as it works not only as a traditional B-lactam but also as an Fe-chelator blocking bacteria from accessing this essential nutrient [i]. It has very good anti-pseudomonas Continue reading Fighting P. aeruginosa (Part II)
In a recent publication Raffi et al. suggest that it may be time to drop efavirenz (Sustiva®) from 1st line HIV treatment recommendations [1]. The authors make the claim that efavirenz was inferior to rilpivirin (Edurant®) and dolutegravir (Tivicay®) in a total of 3 recent controlled studies. They review the CNS side effect profile Continue reading Should Efavirenz Remain a Tier 1 ART Drug?
It has never been easy to cure Pseudomonas aeruginosa infections. Few antibiotics nowadays have reliable activity against this problem pathogen that seems to have more built-in resistance features than most other Gram-negatives. In the past, cephalosporins, aztreonam, penems, ciprofloxacin, and aminoglycosides were useful drugs with reliably cidal activity, especially when Continue reading Fighting P. aeruginosa (Part I)